According to study results presented at the 2007 American Psychiatric Association annual meeting, iloperidone, an investigational atypical antipsychotic, was shown to have a favorable akathisia profile.
The Food and Drug Administration (FDA) approved Lybrel, the first continuous use drug product for prevention of pregnancy.
It is possible that erectile dysfunction (ED) shares a similar pathophysiology with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).
The role of nitric oxide (NO) in the mechanism of erection is well known in the treatment of erectile dysfunction (ED).
Data has shown a correlation between the severity of lower urinary tract symptoms (LUTS) and the severity of erectile dysfunction (ED).
New data demonstrated that the combination asthma therapy, SYMBICORT? (budesonide/formoterol fumarate dihydrate), led to significant improvements in health-related quality of life (HRQL) and greater patient-reported satisfaction with asthma treatment, versus its monocomponents (budesonide or formoterol) or placebo.
In adults with major depressive disorder, adding aripiprazole to antidepressant therapy (ADT) resulted in significant improvement in the primary endpoint, the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score.
Women looking for a simple way to avoid their menstrual period could soon have access the first birth control pill designed to let women suppress monthly menstrual bleeding indefinitely.
GlaxoSmithKline [NYSE:GSK] issued the following response to an article in the New England Journal of Medicine (NEJM) on Avandia? (rosiglitazone maleate), a widely used and highly effective treatment for type 2 diabetes:
It is known that erectile dysfunction (ED), particularly in diabetic men, is often characterized by increased oxidative stress and decreased endothelial function.